Baiyu Pharma Licenses Small Molecule Oncology Drug to Novartis for Up to $1.17 Billion

▎Armstrong

On October 17, 2024, Chengdu Baiyu Pharmaceuticals Co., Ltd. announced that it had licensed a small-molecule anti-tumor drug to Novartis, which paid $70 million upfront, up to $1.1 billion in milestone payments, and corresponding sales royalties.

Chengdu Baiyu Pharmaceuticals Co.,ltd. was founded in 2005,Continuously Focused on the Exploration and Discovery of Ginkgo Molecular-Level Substances' Pharmacological Effects for 20 Years.

Chengdu Baiyu Pharmaceuticals Co.,ltd. R&D Pipeline: Breast Cancer, Including DNA-PK Inhibitors, PARP7 Inhibitors, etc.

Summary

Chengdu's Traditional Pharmaceutical Companies Emerge as Stars in Innovative Drug Transition, Including Kanghong Pharmaceuticals, Developer of Conbercept, Kelun Botai, a Leader in ADC, and Baili Tianheng, a Leader in Bispecific ADC. This transaction involving Chengdu Baiyu Pharmaceuticals Co.,ltd.'s small molecule anticancer drug is also of considerable value.